{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.84","upperLimit":"76.15","value":"68.87"},{"groupId":"OG001","lowerLimit":"38.32","upperLimit":"54.64","value":"46.41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"Overall response rate is defined as the proportion of randomized participants who achieved a best response of PR or better using modified IMWG criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Daratumumab subcutaneously (fixed dose of 1800 mg) or intravenously (16 mg/kg) weekly for cycles 1-2, every 2 weeks for cycles 3-6, and every 4 weeks thereafter. Pomalidomide was administered at a dose of 4 mg orally every day on days 1 through 21, and dexamethasone at 40 mg (or 20 mg for patients ≥75 years of age) orally weekly, in 28-day cycles..\n\nPomalidomide: Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.\n\nDexamethasone: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Daratumumab+Pomalidomide+Dexamethasone"},{"description":"Patients received Pomalidomide at a dose of 4 mg orally every day on days 1 through 21, and dexamethasone 40 mg (or 20 mg for patients ≥75 years of age) orally weekly, in 28-day cycles","id":"OG001","title":"Pomalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"The intent-to-treat (ITT) population was used for efficacy evaluations (total of 304 randomized subjects, 151 in the Daratumumab/Pomalidomide/Dexamethasone group and 153 in the Pomalidomide/Dexamethasone group).","reportingStatus":"POSTED","timeFrame":"Approximately up to 3 years (assessed monthly from randomization until PD).","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}